1)WHO: Towards tuberculosis elimination, an action framework for low-incidence countries. pp3-10, WHO, Geneva, 2014(WHO/HTM/TB/2014.13) https://apps.who.int/iris/bitstream/handle/10665/132231/9789241507707_eng.pdf(2023年1月23日閲覧)
2)阿彦忠之(編),加藤誠也(監):令和4年改訂版 感染症法に基づく結核の接触者健康診断の手引きとその解説—結核の接触者健診Q & A付き—.結核予防会,2022
3)日本結核・非結核性抗酸菌症学会予防委員会:インターフェロンγ遊離試験使用指針2021.結核 96:173-182, 2021
4)Nahid P, et al: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 200: e93-e142, 2019
5)Behr MA, et al: Revisiting the timetable of tuberculosis. BMJ 362: k2738, 2018
6)Seto J, et al: Nosocomial Mycobacterium tuberculosis transmission by brief casual contact identified using comparative genomics. J Hosp Infect 102: 116-119, 2019
7)Seto J, et al: A case of laboratory cross-contamination of Mycobacterium tuberculosis identified using comparative genomics. Int J Tuberc Lung Dis 22: 1239-1242, 2018
8)McElroy PD, et al: A network-informed approach to investigating a tuberculosis outbreak: implications for enhancing contact investigations. Int J Tuberc Lung Dis 7: S486-493, 2003
9)森亨:低まん延下での結核の疫学調査(社会ネットワーク分析の応用).公衆衛生 82:919-925, 2018